EMYRIA LIMITED - Announcements

6.52%

4.3¢

Market Cap $27.51M

Healthcare Biotechnology

Emyria Limited is an Australia-based early-stage drug development company. The Company is... Emyria Limited is an Australia-based early-stage drug development company. The Company is focused on delivering and developing treatments for mental health and select neurological conditions, guided by real-world data collected with patients across its wholly owned clinical service subsidiaries. Its pipeline comprises MDMA analogue drug development and commercialization of novel serotonin-releasing agents. Its Emyria Healthcare provides evidence-based treatment for patients not finding relief from conventional care, while also helping evaluate emerging new therapies like assisted therapy for post-traumatic stress disorder (PTSD) and assisted therapy for treatment-resistant depression. Its Emyria Data is a robust and ethically sourced real-world data gathered with patients and used to improve its therapy and drug development programs. Its Emyria’s Pipeline includes new psychedelic-assisted therapies and drug treatments for mental health and select neurological diseases.More

HELPING PATIENTS ON THEIR JOURNEY TO BETTER HEALTH

Little Green Pharma (ASX:LGP) to benefit as Denmark commits to cannabis pilot program.

Announcements

Filter Results

All Price Sensitive Only

Filters [Clear]

Price Sensitive: Yes

EMD	Positive initial MDMA-analogue screening results	PRICE SENSITIVE	08/12/21	145.86KB	Share
EMD	Emyria receives $1,162,000 R&D Tax Incentive Refund	PRICE SENSITIVE	24/11/21	141.05KB	Share
EMD	Emyria Welcomes Tattarang as Strategic Investor	PRICE SENSITIVE	22/11/21	230.86KB	Share
EMD	Trading Halt	PRICE SENSITIVE	19/11/21	702.94KB	Share
EMD	Appendix 4C - Quarterly	PRICE SENSITIVE	26/10/21	327.47KB	Share
EMD	MDMA Analogue Development Milestone	PRICE SENSITIVE	19/10/21	139.18KB	Share
EMD	Emyria selected to join Palantirs Foundry Builders Program	PRICE SENSITIVE	07/10/21	385.08KB	Share
EMD	Novel MDMA Analogue Screening Program Advanced	PRICE SENSITIVE	22/09/21	145.51KB	Share
EMD	Emyria Expands Psychiatry Advisory for Psychedelics and MDMA	PRICE SENSITIVE	16/09/21	269.06KB	Share
EMD	MDMA-analogues Show Promise for Parkinson's Disease	PRICE SENSITIVE	01/09/21	429.22KB	Share
EMD	Appendix 4E and Full Year Statutory Accounts	PRICE SENSITIVE	31/08/21	1.31MB	Share
EMD	Emyria Engages Calvert Labs for Preclinical CBD studies	PRICE SENSITIVE	27/08/21	144.91KB	Share
EMD	Emyria Appoints Expert Neuropharmacologist for MDMA Program	PRICE SENSITIVE	20/08/21	144.04KB	Share
EMD	Emyria Executes Pure CBD Agreement with AltaSciences	PRICE SENSITIVE	13/08/21	150.95KB	Share
EMD	CAN: Cann and Emyria mutually end collaboration	PRICE SENSITIVE	13/08/21	198.02KB	Share
EMD	Emyria and Cann Mutually End Collaboration	PRICE SENSITIVE	13/08/21	146.93KB	Share
EMD	Emyria to Develop Novel Psychedelics Pipeline with UWA	PRICE SENSITIVE	05/08/21	161.32KB	Share
EMD	Appendix 4C - Quarterly	PRICE SENSITIVE	28/07/21	479.05KB	Share
EMD	Emyria Advances EMD-004 Program Towards Registration	PRICE SENSITIVE	15/06/21	147.96KB	Share
EMD	Emyria Data Validated, Care Model Reduces Opioids	PRICE SENSITIVE	07/06/21	10.36MB	Share
EMD	Emyria Obtains TGA Approval for Medical Grade Monitoring App	PRICE SENSITIVE	12/05/21	439.83KB	Share
EMD	Trading Halt	PRICE SENSITIVE	11/05/21	505.68KB	Share
EMD	Emyria and MMA launch MDMA-assisted therapy program for PTSD	PRICE SENSITIVE	05/05/21	187.44KB	Share
EMD	Appendix 4C - Quarterly	PRICE SENSITIVE	28/04/21	861KB	Share
EMD	$5m Placement for Drug Registration and Treatment Pipeline	PRICE SENSITIVE	21/04/21	146.91KB	Share
EMD	Trading Halt	PRICE SENSITIVE	19/04/21	369.93KB	Share
EMD	Emyria and Cann Partner to Register CBD Product	PRICE SENSITIVE	29/03/21	175.53KB	Share
EMD	Emyria Adds Second Clinical Site in Perth	PRICE SENSITIVE	02/03/21	246.11KB	Share
EMD	Half Yearly Report and Accounts	PRICE SENSITIVE	24/02/21	898.31KB	Share
EMD	Emyria adds second Emerald Clinic in Melbourne	PRICE SENSITIVE	09/02/21	184.75KB	Share
EMD	Emyria wins digital health monitoring grant with UWA	PRICE SENSITIVE	05/02/21	146.04KB	Share
EMD	FDA Position on RWE to Guide Registration	PRICE SENSITIVE	27/01/21	171.85KB	Share
EMD	Appendix 4C - Quarterly	PRICE SENSITIVE	19/01/21	910.72KB	Share
EMD	Emyria Pursuing Registration of EMD-003 in CY2021	PRICE SENSITIVE	05/01/21	148.83KB	Share
EMD	Emyria to Benefit from Final TGA Ruling on CBD Medicines	PRICE SENSITIVE	16/12/20	144.72KB	Share
EMD	Emyria to Accelerate Drug Development with $1.2m Placement	PRICE SENSITIVE	16/12/20	144.58KB	Share
EMD	Trading Halt	PRICE SENSITIVE	14/12/20	507.68KB	Share
EMD	Emyria Sees Strong Interest in IBS Study	PRICE SENSITIVE	03/12/20	246.35KB	Share
EMD	Emyria Launches Drug Development Program Based on RWE	PRICE SENSITIVE	25/11/20	319.37KB	Share
EMD	Emyria Partners with Thought Leaders in Psychedelic Therapy	PRICE SENSITIVE	19/11/20	203.11KB	Share
EMD	Emyria Enters Data Deal with Zelira to Support Autism Trial	PRICE SENSITIVE	09/11/20	242.2KB	Share
EMD	Appendix 4C - Quarterly	PRICE SENSITIVE	29/10/20	358.47KB	Share
EMD	Webinar on Global Partnership with Sapphire Medical Clinics	PRICE SENSITIVE	21/10/20	188.36KB	Share
EMD	Emyria Signs Real-World Data Agreement with Zelira	PRICE SENSITIVE	30/09/20	204.57KB	Share
EMD	Preliminary Final Report and Full Year Statutory Accounts	PRICE SENSITIVE	31/08/20	990.4KB	Share
EMD	Emerald Clinics Successfully Raises $2.2m in Placement	PRICE SENSITIVE	28/08/20	171.55KB	Share
EMD	Trading Halt	PRICE SENSITIVE	27/08/20	344.41KB	Share
EMD	Record Appointments International Expansion and Name Change	PRICE SENSITIVE	14/08/20	196.21KB	Share
EMD	Emerald Signs RWE Contract with Canopy Growth UK Company	PRICE SENSITIVE	10/08/20	203.83KB	Share
EMD	Appendix 4C - Quarterly	PRICE SENSITIVE	31/07/20	476.92KB	Share
EMD	EMDs Digital Health Platform Expands with New Technology	PRICE SENSITIVE	22/06/20	204.87KB	Share
EMD	Trading Halt	PRICE SENSITIVE	18/06/20	215.75KB	Share
EMD	EMD Program Manager of National Clinical Data and Analytics	PRICE SENSITIVE	11/05/20	224.18KB	Share
EMD	Appendix 4C - Quarterly	PRICE SENSITIVE	30/04/20	353.16KB	Share
EMD	Half Yearly Report and Accounts	PRICE SENSITIVE	28/02/20	620.1KB	Share
EMD	ZLD: Phase 1 Opioid Reduction Clinical Trial Fully Enrolled	PRICE SENSITIVE	27/02/20	160.74KB	Share

EMD Positive initial MDMA-analogue screening results
08/12/21	PRICE SENSITIVE	145.86KB	Share
EMD Emyria receives $1,162,000 R&D Tax Incentive Refund
24/11/21	PRICE SENSITIVE	141.05KB	Share
EMD Emyria Welcomes Tattarang as Strategic Investor
22/11/21	PRICE SENSITIVE	230.86KB	Share
EMD Trading Halt
19/11/21	PRICE SENSITIVE	702.94KB	Share
EMD Appendix 4C - Quarterly
26/10/21	PRICE SENSITIVE	327.47KB	Share
EMD MDMA Analogue Development Milestone
19/10/21	PRICE SENSITIVE	139.18KB	Share
EMD Emyria selected to join Palantirs Foundry Builders Program
07/10/21	PRICE SENSITIVE	385.08KB	Share
EMD Novel MDMA Analogue Screening Program Advanced
22/09/21	PRICE SENSITIVE	145.51KB	Share
EMD Emyria Expands Psychiatry Advisory for Psychedelics and MDMA
16/09/21	PRICE SENSITIVE	269.06KB	Share
EMD MDMA-analogues Show Promise for Parkinson's Disease
01/09/21	PRICE SENSITIVE	429.22KB	Share
EMD Appendix 4E and Full Year Statutory Accounts
31/08/21	PRICE SENSITIVE	1.31MB	Share
EMD Emyria Engages Calvert Labs for Preclinical CBD studies
27/08/21	PRICE SENSITIVE	144.91KB	Share
EMD Emyria Appoints Expert Neuropharmacologist for MDMA Program
20/08/21	PRICE SENSITIVE	144.04KB	Share
EMD Emyria Executes Pure CBD Agreement with AltaSciences
13/08/21	PRICE SENSITIVE	150.95KB	Share
EMD CAN: Cann and Emyria mutually end collaboration
13/08/21	PRICE SENSITIVE	198.02KB	Share
EMD Emyria and Cann Mutually End Collaboration
13/08/21	PRICE SENSITIVE	146.93KB	Share
EMD Emyria to Develop Novel Psychedelics Pipeline with UWA
05/08/21	PRICE SENSITIVE	161.32KB	Share
EMD Appendix 4C - Quarterly
28/07/21	PRICE SENSITIVE	479.05KB	Share
EMD Emyria Advances EMD-004 Program Towards Registration
15/06/21	PRICE SENSITIVE	147.96KB	Share
EMD Emyria Data Validated, Care Model Reduces Opioids
07/06/21	PRICE SENSITIVE	10.36MB	Share
EMD Emyria Obtains TGA Approval for Medical Grade Monitoring App
12/05/21	PRICE SENSITIVE	439.83KB	Share
EMD Trading Halt
11/05/21	PRICE SENSITIVE	505.68KB	Share
EMD Emyria and MMA launch MDMA-assisted therapy program for PTSD
05/05/21	PRICE SENSITIVE	187.44KB	Share
EMD Appendix 4C - Quarterly
28/04/21	PRICE SENSITIVE	861KB	Share
EMD $5m Placement for Drug Registration and Treatment Pipeline
21/04/21	PRICE SENSITIVE	146.91KB	Share
EMD Trading Halt
19/04/21	PRICE SENSITIVE	369.93KB	Share
EMD Emyria and Cann Partner to Register CBD Product
29/03/21	PRICE SENSITIVE	175.53KB	Share
EMD Emyria Adds Second Clinical Site in Perth
02/03/21	PRICE SENSITIVE	246.11KB	Share
EMD Half Yearly Report and Accounts
24/02/21	PRICE SENSITIVE	898.31KB	Share
EMD Emyria adds second Emerald Clinic in Melbourne
09/02/21	PRICE SENSITIVE	184.75KB	Share
EMD Emyria wins digital health monitoring grant with UWA
05/02/21	PRICE SENSITIVE	146.04KB	Share
EMD FDA Position on RWE to Guide Registration
27/01/21	PRICE SENSITIVE	171.85KB	Share
EMD Appendix 4C - Quarterly
19/01/21	PRICE SENSITIVE	910.72KB	Share
EMD Emyria Pursuing Registration of EMD-003 in CY2021
05/01/21	PRICE SENSITIVE	148.83KB	Share
EMD Emyria to Benefit from Final TGA Ruling on CBD Medicines
16/12/20	PRICE SENSITIVE	144.72KB	Share
EMD Emyria to Accelerate Drug Development with $1.2m Placement
16/12/20	PRICE SENSITIVE	144.58KB	Share
EMD Trading Halt
14/12/20	PRICE SENSITIVE	507.68KB	Share
EMD Emyria Sees Strong Interest in IBS Study
03/12/20	PRICE SENSITIVE	246.35KB	Share
EMD Emyria Launches Drug Development Program Based on RWE
25/11/20	PRICE SENSITIVE	319.37KB	Share
EMD Emyria Partners with Thought Leaders in Psychedelic Therapy
19/11/20	PRICE SENSITIVE	203.11KB	Share
EMD Emyria Enters Data Deal with Zelira to Support Autism Trial
09/11/20	PRICE SENSITIVE	242.2KB	Share
EMD Appendix 4C - Quarterly
29/10/20	PRICE SENSITIVE	358.47KB	Share
EMD Webinar on Global Partnership with Sapphire Medical Clinics
21/10/20	PRICE SENSITIVE	188.36KB	Share
EMD Emyria Signs Real-World Data Agreement with Zelira
30/09/20	PRICE SENSITIVE	204.57KB	Share
EMD Preliminary Final Report and Full Year Statutory Accounts
31/08/20	PRICE SENSITIVE	990.4KB	Share
EMD Emerald Clinics Successfully Raises $2.2m in Placement
28/08/20	PRICE SENSITIVE	171.55KB	Share
EMD Trading Halt
27/08/20	PRICE SENSITIVE	344.41KB	Share
EMD Record Appointments International Expansion and Name Change
14/08/20	PRICE SENSITIVE	196.21KB	Share
EMD Emerald Signs RWE Contract with Canopy Growth UK Company
10/08/20	PRICE SENSITIVE	203.83KB	Share
EMD Appendix 4C - Quarterly
31/07/20	PRICE SENSITIVE	476.92KB	Share
EMD EMDs Digital Health Platform Expands with New Technology
22/06/20	PRICE SENSITIVE	204.87KB	Share
EMD Trading Halt
18/06/20	PRICE SENSITIVE	215.75KB	Share
EMD EMD Program Manager of National Clinical Data and Analytics
11/05/20	PRICE SENSITIVE	224.18KB	Share
EMD Appendix 4C - Quarterly
30/04/20	PRICE SENSITIVE	353.16KB	Share
EMD Half Yearly Report and Accounts
28/02/20	PRICE SENSITIVE	620.1KB	Share
EMD ZLD: Phase 1 Opioid Reduction Clinical Trial Fully Enrolled
27/02/20	PRICE SENSITIVE	160.74KB	Share

REFRESH

First

Add to My Watchlist

What is My Watchlist?

A personalised tool to help users track selected stocks. Delivering real-time notifications on price updates, announcements, and performance stats on each to help make informed investment decisions.

(20min delay)
Last 4.3¢		Change -0.003(6.52%)		Mkt cap ! $27.51M

Open	High	Low	Value	Volume
4.8¢	4.8¢	4.3¢	$70.41K	1.564M

Buyers (Bids)

No.	Vol.	Price($)
3	365706	4.2¢

Sellers (Offers)

Price($)	Vol.	No.
4.4¢	55848	3

View Market Depth

No.	Vol.	Price($)
2	59530	0.043
2	350084	0.042
3	302469	0.041
8	189085	0.040
4	195172	0.039

Price($)	Vol.	No.
0.044	126491	4
0.045	42213	2
0.047	130429	2
0.048	578511	4
0.049	560000	5

Last trade - 13.26pm 11/08/2025 (20 minute delay)


Last 4.2¢		Change -0.003 ( 8.70 %)
Open	High	Low	Volume
4.6¢	4.6¢	4.2¢	671653
Last updated 13.33pm 11/08/2025 ?

EMD (ASX) Chart

EMYRIA LIMITED - Announcements

Announcements

Buyers (Bids)

Sellers (Offers)

Top Stories